The discovery of novel experimental therapies for inflammatory arthritis

Mediators of Inflammation

Volumn 2009, Issue , 2009, Pages

  Malemud, Charles J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 ACETYL 4 (1,2,3,4 TETRAHYDROXYBUTYL)IMIDAZOLE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTIRHEUMATIC AGENT; ARRY 162; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; FOSTAMATINIB; FR 180204; GLPG 0259; INDOLE 5 CARBOXAMIDE; INTERLEUKIN 7 RECEPTOR ALPHA; LX 2931; METHOTREXATE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PLACEBO; POLYUBIQUITIN; PROTEASOME; PROTEIN KINASE SYK; R 406; R 788; SD 282; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTACOID; DRUG DERIVATIVE; INTERLEUKIN 7 RECEPTOR; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; DIARRHEA; DRUG DEVELOPMENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; VALIDATION STUDY; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; INFLAMMATION; METABOLISM;

ANIMALIA;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; DRUG DISCOVERY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOPHOSPHOLIPIDS; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE KINASES; RECEPTORS, INTERLEUKIN-7; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SPHINGOSINE;

EID: 77953643594     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2009/698769     Document Type: Review

References (145)

1. M.G.Feely, A. Erickson,and J. R. O'Dell,"Therapeutic options for rheumatoid arthritis," Expert Opinion on Pharmacotherapy, vol. 10, no. 13, pp. 2095-2106, 2009.
2. L. G. Schipper, J. Fransen, P. Barrera, and P. L. C. M. van Riel, "Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naivetobothdrugs," Rheumatology, vol. 48, no. 7, pp. 828-833, 2009.
3. M. L. Hetland, K. Stengaard-Pedersen, P. Junker, et al., "Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second- year clinical and radiographic results from the CIMESTRA study," Annals of the Rheumatic Diseases,vol. 67, no.6,pp. 815-822,2008.
4. M. Khraishi, "Comparative overview of safety of the biologics in rheumatoid arthritis," Journal of Rheumatology, vol. 36, supplement 82, pp. 25-32, 2009.
5. L. J. Gibbons and K. L. Hyrich, "Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response," BioDrugs, vol. 23, no. 2, pp. 111-124, 2009.
6. D. E. Furst, "Certolizumab pegol-what role does this new TNF inhibitor have in the treatment of RA?" Nature Clinical Practice Rheumatology, vol. 5, no. 3, pp. 134-135, 2009.
7. V. Oldfield and G. L. Plosker, "Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis," BioDrugs, vol. 23, no. 2, pp. 125-135, 2009.
8. M. Mertens and J. A. Singh, "Anakinra for rheumatoid arthritis," Cochrane Database of Systematic Reviews,no. 1, Article ID CD005121, 2009.
9. L. Senolt, J. Vencovsky, K. Pavelka, C. Ospelt, and S. Gay, "Prospective new biological therapies for rheumatoid arthritis," Autoimmunity Reviews, vol. 9, no. 2, pp. 102-107, 2009.
10. L. D. Churchand, M.F.McDermott,"Canakinumab,a fully-human mAb against IL-1// for the potential treatment of inflammatory disorders," Current Opinion in Molecular Therapeutics, vol. 11, no. 1, pp. 81-89, 2009.
11. V. Goëb, M. H. Buch, E. M. Vital, and P. Emery, "Costimula- tion blockade in rheumatic diseases: where we are?" Current Opinion in Rheumatology, vol. 21, no. 3, pp. 244-250, 2009.
12. B. Laganà, M. Vinciguerra, and R. D'Amelio, "Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept," Clinical Drug Investigation, vol. 29, no. 3, pp. 185-202, 2009.
13. A. J. K. Ostör, "Abatacept: a T-cell co-stimulation modulator for the treatment ofrheumatoid arthritis," Clinical Rheumatology, vol. 27, no. 11, pp. 1343-1353, 2008.
14. S. Dass, E. M. Vital, and P. Emery, "Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis," Expert Opinion on Pharmacotherapy, vol. 7, no. 18, pp. 2559-2570, 2006.
15. M. Nakou, G. Katsikas, P. Sidiropoulos, et al., "Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response," Arthritis Research & Therapy, vol. 11, no. 4, article R131,2009.
16. R. Caporali, M. Caprioli, F. Bobbio-Pallavicini, S. Bugatti, and C. Montecucco, "Long term treatment of rheumatoid arthritis with rituximab," Autoimmunity Reviews, vol. 8, no. 7, pp. 591-594, 2009.
17. A. Finckh and C. Gabay, "At the horizon of innovative therapy in rheumatology: new biologic agents," Current Opinion in Rheumatology, vol. 20, no. 3, pp. 269-275, 2008.
18. F. De Benedetti, "Targeting interleukin-6 in pediatric rheumatic diseases," Current Opinion in Rheumatology, vol. 21, no. 5, pp. 533-537, 2009.
19. J. van der Heijden, M. C. de Jong, B. A. Dijkmans, et al., "Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non- related DMARDs," Annals ofthe Rheumatic Diseases, vol. 63, no. 2, pp. 131-137, 2004.
20. A. Gibofsky, W. R. Palmer, J. A. Goldman, et al., "Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study," Current Medical Research and Opinion, vol. 22, no. 1, pp. 169-183, 2006.
21. W. Kievit, J. Fransen, A.J.M. Oerlemans, et al., "The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice," Annals of the Rheumatic Diseases, vol. 66, no. 11, pp. 1473-1478, 2007.
22. J. D. Greenberg, M. Kishimoto, V. Strand, et al., "Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort," American Journal ofMedicine, vol. 121, no. 6, pp. 532-538, 2008.
23. C. Salliot, M. Dougados, L. Gossec, "Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses ofrandomised placebo-controlled trials", Annals ofthe Rheumatic Diseases, Vol. 68, no. 1, pp. 25-32, 2009.
24. J. P. Leombruno, T. R. Einarson, and E. C. Keystone, "The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events," Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1136-1145, 2009.
25. C. J. Malemud, "Defining novel targets for intervention in rheumatoid arthritis: an overview," Current Rheumatology Reviews, vol. 4, no. 4, pp. 214-218, 2008.
26. C. J. Malemud and E. Pearlman, "Targeting JAK/STAT signaling pathway in inflammatory diseases," Current Signal Transduction Therapy, vol. 4, no. 4, pp. 201-221, 2009.
27. C. J. Malemud, "Inhibitors of stress-activated protein/ mitogen-activated protein kinase pathways," Current Opinion in Pharmacology, vol. 7, no. 3, pp. 339-343, 2007.
28. S. C. Karcher and S. A. Laufer, "Successful structure-based design of recent p38 MAP kinase inhibitors," Current Topics in Medicinal Chemistry, vol. 9, no. 7, pp. 655-676, 2009.
29. T. Mima and N. Nishimoto, "Clinical value of blocking IL- 6receptor,"Current Opinion in Rheumatology, vol. 21, no. 3, pp. 224-230, 2009.
30. C. J. Malemud, "Recent advances in neutralizing the IL-6 pathway in arthritis," Open Access Rheumatology: Research & Reviews, vol. 1, no. 1, pp. 1-18, 2009.
31. S. E. Alvarez, S. Milstien, and S. Spiegel, "Autocrine and paracrine roles of sphingosine-1-phosphate," Trends in Endocrinology and Metabolism, vol. 18, no. 8, pp. 300-307, 2007.
32. A. J. Melendez, "Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets," Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 66-75, 2008.
33. A. Weigert, N. Weis, and B. Brune, "Regulation of macrophage function by sphingosine-1-phosphate," Immunobiology, vol. 214, no. 9-10, pp. 748-760, 2009.
34. I. Ishii, N. Fukushima, X. Ye, and J. Chun, "Lysophospholipid receptors: signaling and biology," Annual Review ofBiochemistry, vol. 73, pp. 321-354, 2004.
35. N. C. Hait, C. A. Oskeritzian, S. W. Paugh, S. Milstien, and S. Spiegel, "Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases," Biochimica et Biophysica Acta, vol. 1758, no. 12, pp. 2016-2026, 2006.
36. C. J. Malemud and H. J. Gillespie, "The role of apoptosis in arthritis," Current Rheumatology Reviews,vol. 1,no.2,pp. 131-142, 2005.
37. J. Hutcheson and H. Perlman, "Apoptotic regulators and RA," Current Rheumatology Reviews, vol. 4, no. 4, pp. 254-258, 2008.
38. C. J. Malemud and M. E. Schulte, "Is there a final common pathway for arthritis?" Future Rheumatology,vol. 3, no. 3, pp. 253-268, 2008.
39. Y. Kariya, A. Kihara, M. Ikeda, et al., "Products by the sphingosine kinase/sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis," Genes to Cells, vol. 10, no. 6, pp. 605-615, 2005.
40. J. T. Bagdanoff, M. S. Donoviel, A. Nouraldeen, et al., "Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders," Journal ofMedicinal Chemistry, vol. 52, no. 13, pp. 3941-3953, 2009.
41. A. Billich and T. Baumruker, "Sphingolipid metabolizing enzymes as novel therapeutics," Subcellular Biochemistry, vol. 49, pp. 487-522, 2008.
42. http://www.mskreport.com/articles.cfm?articleID=3416.
43. B. J. Pettus, J. Bielawski, A. M. Porcelli, et al., "The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF- α," FASEB Journal, vol. 17, no. 11, pp. 1411-1421,2003.
44. D. Mechtcheriakova, A. Wlachos, J. Sobanov, et al., "Sph- ingosine 1-phosphate phosphatase 2 is induced during inflammatory responses," Cellular Signalling, vol. 19, no. 4, pp. 748-760, 2007.
45. K. Akashi, M. Kondo, and I. L. Weissman, "Role of interleukin-7 in T-cell development from hematopoietic stem cells," Immunological Reviews, vol. 165, pp. 13-28, 1998.
46. M. Saini, C. Pearson, and B. Seddon, "Regulation of T cell- dendritic cell interactions by IL-7 governs T-cell activation and homeostasis," Blood, vol.113, no.23, pp. 5793-5800, 2009.
47. T. K. Vogt, A. Link, J. Perrin, D. Finke, and S. A. Luther, "Novel function for interleukin-7 in dendritic cell development," Blood, vol.113, no.17, pp. 3961-3968, 2009.
48. S. Schmutz, N. Bosco, S. Chappaz, et al., "Cutting edge: IL- 7 regulates the peripheral pool of adult ROR γ+ lymphoid tissue inducer cells," Journal of Immunology, vol.183, no.4, pp. 2217-2221,2009.
49. A. H. Banham, "Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells," Trends in Immunology, vol.27, no.12, pp. 541-544, 2006.
50. P. M. Appasamy, "Biological and clinical implications of interleukin-7 and lymphopoiesis," Cytokines, Cellular and Molecular Therapy, vol.5, no.1, pp. 25-39, 1999.
51. C. J. Malemud and S. K. Reddy, "Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis," Current RheumatologyReviews, vol.4, no.4, pp. 219-234, 2008.
52. K. Akashi, M. Kondo, U. von Freeden-Jeffry, R. Murray, and I. L. Weissman, "Bcl-2 rescues T lymphopoiesis in interleukin- 7 receptor-deficient mice," Cell, vol.89, no.7, pp. 1033-1041, 1997.
53. A. R. Khaled, W. Q. Li, J. Huang, et al., "Bax deficiency partially corrects interleukin-7 receptor α deficiency," Immunity, vol.17, no.5, pp. 561-573, 2002.
54. E. Sitnicka, C. Brakebusch, I.-L. Martensson, et al., "Complementary signaling through flt3 and interleukin-7 receptor α is indispensable for fetal and adult B cell genesis," Journal of Experimental Medicine, vol.198, no.10, pp. 1495-1506,2003.
55. S. M. Churchman and F. Ponchel, "Interleukin-7 in rheumatoid arthritis," Rheumatology, vol.47, no.6, pp. 753-759, 2008.
56. S.-I. Sawa, D. Kamimura, G.-H. Jin, et al., "Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells," Journal of Experimental Medicine, vol.203, no.6, pp. 1459-1470, 2006.
57. H.-R. Kim, K.-A. Hwang, S.-H. Park, and I. Kang, "IL-7 and IL-15: biology and roles in T-cell immunity in health and disease," Critical Reviews in Immunology, vol.28, no.4, pp. 325-339, 2008.
58. S. A. Y. Hartgring,J.W.J.Bijlsma,F.P.J.G.Lafeber,and J. A. G. van Roon, "Interleukin-7 induced immunopathology in arthritis," Annals of the Rheumatic Diseases, vol.65, supplement 3, pp. iii69-iii74, 2006.
59. J. A. G. van Roon, S. A. Y. Hartgring, M. W.-V. Wijk, et al., "Persistence of interleukin 7 activity and levels on tumour necrosis factor α blockade in patients with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol.66, no.5, pp. 664-669, 2007.
60. S. A. Y. Hartgring, J.A.G. Van Roon, M.W.V. Wijk, et al., "Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis," Arthritis and Rheumatism, vol.60, no.9, pp. 2595-2605, 2009.
61. N. K. Vudattu, S. Kuhlmann-Berenzon, M. Khademi, V. Seyfert, T. Olsson, and M. J. Maeurer, "Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system," PLoS ONE, vol.4, no.8, article e6534, 2009.
62. C. J. Malemud, "Role of nonreceptor tyrosine and threonine kinase inhibitors," in Molecular Biology of Cancer: Toward New Therapies, J. García-Foncillas, Ed., pp. 537-555, Prous Science, Barcelona, Spain, 2009.
63. B. R. Wong, E. B. Grossbard, D. G. Payan, and E. S. Masuda, "Targeting Syk as a treatment for allergic and autoimmune disorders," Expert Opinion on Investigational Drugs, vol.13, no.7, pp. 743-762, 2004.
64. N. Rao, A. K. Ghosh, S. Ota, et al., "The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation," EMBO Journal, vol.20, no.24, pp. 7085-7095, 2002.
65. A. G. Tristano, "Tyrosine kinases as targets in rheumatoid arthritis," International Immunopharmacology, vol.9, no.1, pp. 1-9, 2009.
66. M. Bajpai, P. Chopra, S. G. Dastidar, and A. Ray, "Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis," Expert Opinion on Investigational Drugs, vol.17, no.5, pp. 641-659, 2008.
67. M. Hikida, S. Casola, N. Takahashi, et al., "PLCγ2 is essential for formation and maintenance of memory B cells," Journal of Experimental Medicine, vol.206, no.3, pp. 681-689, 2009.
68. P. R. Pine, B. Chang, N. Schoettler, et al., "Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor," Clinical Immunology, vol.124, no.3, pp. 244-257, 2007.
69. M. Bajpai, "Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases," IDrugs,vol.12, no.3, pp. 174-185,2009.
70. M. E. Weinblatt, A. Kavanaugh, R. Burgos-Vargas, et al., "Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial," Arthritis and Rheumatism, vol.58, no.11, pp. 3309-3318, 2008.
71. C. J. Malemud, "Protein kinases in chondrocyte signaling and osteoarthritis," Clinical Orthopaedics and Related Research, no.427, supplement, pp. S145-S151, 2004.
72. G. L. Johnson, H. G. Dohlman, and L. M. Graves, "MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression," Current Opinion in Chemical Biology, vol.9, no.3, pp. 325-331,2005.
73. C. J. Malemud, "MAP kinases," in OA, Inflammation and Degradation: A Continuum, J. Buckwalter, M. Lotz, and J.- F. Stoltz, Eds., vol.70 of Biomedical and Health Research, pp. 99-117, IOS Press, Amsterdam, The Netherlands, 2007.
74. I. Breitkreutz, M. S. Raab, S. Vallet, et al., "Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma," British Journal of Haematology, vol.139, no.1, pp. 55-63, 2007.
75. H. Hotokezaka, E. Sakai, K. Kanaoka, et al., "U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells," The Journal of Biological Chemistry, vol.277, no.49, pp. 47366-47372, 2002.
76. J. M. Waldburger and G. S. Firestein, "Garden of therapeutic delights: new targets in rheumatic diseases," Arthritis Research and Therapy, vol.11, no.1, article 206, 2009.
77. H. B. Kwak, H.M.Sun, H. Ha, J.H.Lee, H.N.Kim, and Z. H. Lee, "AG490, a Jak2-specific inhibitor, induces osteoclast survival by activating the Akt and ERK signaling pathways," Molecules and Cells, vol.26, no.5, pp. 436-442, 2008.
78. L. C. Hof bauer and M. Schoppet, "Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases," Journal of the American Medical Association, vol.292, no.4, pp. 490-495, 2004.
79. A.E. Kearns,S.Khosla,andP.J.Kostenuik,"Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease," Endocrine Reviews, vol.29, no.2, pp. 155-192, 2008.
80. J. A. McCubrey, M. Milella, A. Tafuri, et al., "Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors," Current Opinion in Investigational Drugs,vol. 9,no.6,pp. 614-630, 2008.
81. J. A. McCubrey, L. S. Steelman, S. L. Abrams, et al., "Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance," Advances in Enzyme Regulation, vol.46, no.1, pp. 249-279, 2006.
82. M. J. Thiel, C. J. Schaefer, M. E. Lesch, et al., "Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms," Arthritis and Rheumatism, vol.56, no.10, pp. 3347-3357, 2007.
83. M. Ohori, "ERK inhibitors as a potential new therapy for rheumatoid arthritis," Drug News and Perspectives, vol.21, no.5, pp. 245-250, 2008.
84. http://www.pharmalive.com/News/Index.cfm?articleid=649388.
85. Y. Nagata, T. Nakasa, Y. Mochizuki, et al., "Induction of apoptosis in the synovium of mice with autoantibody- mediated arthritis by the intraarticular injection of double- stranded microRNA-15a," Arthritis and Rheumatism, vol.60, no.9, pp. 2677-2683, 2009.
86. Q. Yao, D. W. Seol, Z. Mi, and P. D. Robbins, "Intra- articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis," Arthritis Research & Therapy, vol.8, no.1, article R16, 2006.
87. S.-W. Lee, J.-H. Kim, Y.-B. Park, and S.-K. Lee, "Bortezomib attenuates murine collagen-induced arthritis," Annals of the Rheumatic Diseases, vol.68, no.11, pp. 1761-1767, 2009.
88. L. New, Y. Jiang, M. Zhao, et al., "PRAK, a novel protein kinase regulated by the p38 MAP kinase," EMBO Journal, vol.17, no.12, pp. 3372-3384, 1998. (Pubitemid 28279511)
89. M.Perander, S.M.Keyse, and O.-M.Seternes,"DoesMK5 reconcile classical and atypical MAP kinases?" Frontiers in Bioscience, vol.13, no.12, pp. 4617-4624, 2008.
90. E. Åberg, M. Perander, B. Johansen, et al., "Regulation of MAPK-activated protein kinase 5 activity and subcellularlocalization by the atypical MAPK ERK4/MAPK4," The Journal of Biological Chemistry, vol.281, no.46, pp. 35499-35510,2006.
91. M. Gaestel, "Specificity of signaling from MAPKs to MAP- KAPKs: kinases' tango nuevo," Frontiers in Bioscience, vol.13, pp. 6050-6059, 2008.
92. S. Kostenko, M. Johannessen, and U. Moens, "PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5," Cellular Signalling, vol.21, no.5, pp. 712-718, 2009.
93. K. L. Wood, H. L. Twigg III, and A. I. Doseff,"Dysregu- lation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation," Frontiers in Bioscience, vol.14, pp. 3771-3781,2009.
94. M. F. Roelof s, W. C. Boelens, L. A. B. Joosten, et al., "Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis," Journal of Immunology, vol.176, no.11, pp. 7021-7027, 2006.
95. E. Åberg, K. M. Torg ersen, B. Johansen, S. M. Keyse, M. Perander, and O.-M. Seternes, "Docking of PRAK/MK5 to the atypical MAPKs ERK3 and ERK4 defines a novel MAPK interaction motif," The Journal of Biological Chemistry, vol.284, no.29, pp. 19392-19401, 2009.
96. M. Yoshida, M. Niwa, A. Ishisaki, et al., "Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts," Prostaglandins Leukotrienes and Essential Fatty Acids, vol.71, no.6, pp. 351-362, 2004.
97. S. Medicherla, J. Y. Ma, R. Mangadu, et al., "A selective p38α mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis," Journal of Pharmacology and Experimental Therapeutics, vol.318, no.1, pp. 132-141, 2006.
98. N. Gerits, A. Shiryaev, S. Kostenko, et al., "The tran- scriptional regulation and cell-specific expression of the MAPK-activated protein kinase MK5," Cellular and Molecular Biology Letters, vol.14, no.4, pp. 548-574, 2009.
99. P. Sun, N. Yoshizuka, L. New, et al., "PRAK Is essential for ras- induced senescence and tumor suppression," Cell, vol.128, no.2, pp. 295-308, 2007.
100. 2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts: role in suppression of c/EBP/NF-κB-mediated MEKK1-induced MMP-1 expression," The Journal of Biological Chemistry, vol.281, no.29, pp. 19849-19860, 2006.
101. E. Šimelyte,S.Rosengren,D.L.Boyle,M.Corr, D. R. Green, and G. S. Firestein, "Regulation of arthritis by p53: critical role of adaptive immunity," Arthritis and Rheumatism, vol.52, no.6, pp. 1876-1884, 2005.
102. http://nmcc-vikas.gov.in/AhmedabadPharma/Galapagoshtml.
103. M. Fabbri, C. M. Croce, and G. A. Calin, "MicroRNAs," Cancer Journal, vol.14, no.1, pp. 1-6, 2008.
104. H. F. Lodish, B. Zhou, G. Liu, and C.-Z. Chen, "Micro- management of the immune system by microRNAs," Nature Reviews Immunology, vol.8, no.2, pp. 120-130, 2008.
105. B. P. Lewis, C. B. Burge, and D. P. Bartel, "Conserved seed pairing, of ten flanked by adenosines, indicates that thousands of human genes are microRNA targets," Cell, vol.120, no.1,pp. 15-20, 2005.
106. E. Karouzakis, R. E. Gay, S. Gay, and M. Neidhart, "Epige- netic control in rheumatoid arthritis synovial fibroblasts," Nature Reviews Rheumatology, vol.5, no.5, pp. 266-272, 2009.
107. K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, "NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses," Proceedings of the National Academy of Sciences of the United States of America, vol.103, no.33, pp. 12481-12486, 2006.
108. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, "MicroRNA-155 is induced during the macrophage inflammatory response," Proceedings of the National Academy of Sciences of the United States of America, vol.104, no.5, pp. 1604-1609, 2007.
109. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol.116, no.2, pp. 281-297, 2004.
110. T. Nakasa, S. Miyaki, A. Okubo, et al., "Expression of microRNA-146 in rheumatoid arthritis synovial tissue," Arthritis and Rheumatism, vol.58, no.5, pp. 1284-1292, 2008.
111. J. Stanczyk, D. M. L. Pedrioli, F. Brentano, et al., "Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis," Arthritis and Rheumatism, vol.58, no.4, pp. 1001-1009, 2008.
112. K. M. Pauley, M. Satoh, A. L. Chan, M. R. Bubb, W. H. Reeves, and E. K. L. Chan, "Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients," Arthritis Research and Therapy, vol.10, no.4, article R101, 2008.
113. M. K. Ameriks and J. D. Venable, "Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) δ and γ," Current Topics in Medicinal Chemistry, vol.9, no.8, pp. 738-753, 2009.
114. C. Rommel, M. Camps, and H. Ji, "PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?" Nature Reviews Immunology,vol.7,no.3,pp. 191-201,2007.
115. E. H. Kang, D. J. Kim, E. Y. Lee, Y. J. Lee, E. B. Lee, and Y. W. Song, "Downregulation of heat shock protein 70 protects rheumatoid arthritis fibroblast-like synoviocytes from nitric oxide-induced apoptosis," Arthritis Research & Therapy, vol.11, no.4, article R130, 2009.
116. Y. Lin, C.-C. Su, J.-Y. Huang, et al., "Aberrant integrin activation induces p38 MAPK phosphorylation resulting in suppressed Fas-mediated apoptosis in T cells: implications for rheumatoid arthritis," Molecular Immunology, vol.46, no.16, pp. 3328-3335,2009.
117. A. K. Mankan, M. W. Lawless, S. G. Gray, D. Kelleher, and R. McManus, "NF-κB regulation: the nuclear response," Journal of Cellular and Molecular Medicine, vol.13, no.4, pp. 631-643, 2009.
118. S. Palmer and Y. H. Chen, "Bcl-3, a multifaceted modulator of NF-κB-mediated gene transcription," Immunologic Research, vol.42, no.1-3, pp. 210-218, 2008.
119. U. Meusch, M. Rossol, C. Baerwald, S. Hauschildt, and U. Wagner, "Outside-to-inside signaling through transmem- brane tumor necrosis factor reverses pathologic interleukin- 1/3 production and deficient apoptosis of rheumatoid arthritis monocytes," Arthritis and Rheumatism,vol.60,no.9,pp. 2612-2621,2009.
120. D. C. Phillips, H. I. Dias, G. D. Kitas, and H. R. Griffiths, "Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival and therapeutic intervention," Antioxid Redox Signal. In press.
121. J. Hutcheson and H. Perlman, "BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention," Oncogene, vol.27, supplement 1, pp. S168-S175, 2008.
122. C. Falschlehner, T. M. Ganten, R. Koschny, U. Schaefer, and H. Walczak, "TRAIL and other TRAIL receptor agonists as novel cancer therapeutics," Advances in Experimental Medicine and Biology, vol.647, pp. 195-206, 2009.
123. J. Morel, R. Audo, M. Hahne, and B. Combe, "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phos- phatidylinositol 3-kinase/Akt," The Journal of Biological Chemistry, vol.280, no.16, pp. 15709-15718, 2005.
124. A. Jüngel, V. Baresova, C. Ospelt, et al., "Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis," Annals of the Rheumatic Diseases, vol.65, no.7, pp. 910-912, 2006.
125. M. Tamai, A. Kawakami, F. Tanaka, et al., "Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-y through JAK/STAT pathway by translational regulation," Journal of Laboratory and Clinical Medicine, vol.147, no.4, pp. 182-190,2006.
126. M. Bonmort, E. Ullrich, G. Mignot, B. Jacobs, N. Chaput, and L. Zitvogel, "Interferon-γ is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC)," Biochimie, vol.89, no.6-7, pp. 872-877, 2007.
127. S. Häcker, A. Dittrich, A. Mohr, et al., "Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers withsilencing of caspase-8," Oncogene, vol.28, no.35, pp. 3097-3110, 2009.
128. R. Audo, B. Combe, B. Coulet, J. Morel, and M. Hahne, "The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases," Cell Death and Differentiation, vol.16, no.9, pp. 1227-1237, 2009.
129. N. Pundt, M. A. Peters, C. Wunrau, et al., "Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent," Arthritis Research and Therapy, vol.11, no.1, article R16, 2009.
130. E. Terzioglu, A. Bisgin, A. D. Sanlioglu, et al., "Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis," Rheumatology, vol.46, no.5, pp. 783-789, 2007.
131. X. Liu, P. Yue, F. R. Khuri, and S.-Y. Sun, "Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity," Cancer Research, vol.65, no.20, pp. 9169-9175, 2005.
132. C. J. Malemud, "Gene therapy for arthritis: defining novel gene targets," Gene Therapy and Molecular Biology, vol.11, no.1, pp. 27-36, 2007.
133. J. Adams, "The proteasome: a suitable antineoplastic target," Nature Reviews Cancer, vol.4, no.5, pp. 349-360, 2004.
134. J. M. Peters, W. W. Franke, and J. A. Kleinschmidt, "Distinct 19S and 20S subcomplexes of the 26S proteasome and their distribution in the nucleus and cytoplasm," The Journal of Biological Chemistry, vol.269, no.10, pp. 7709-7718, 1994.
135. J. Wang and M. A. Maldonado, "The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases," Cellular & Molecular Immunology,vol.3,no.4,pp. 255-261,2006.
136. P. J. Elliott, T. M. Zollner, and W.-H. Boehncke, "Proteasome inhibition: a new anti-inflammatory strategy," Journal of Molecular Medicine, vol.81, no.4, pp. 235-245, 2003.
137. M. K. Bennett and C. J. Kirk, "Development of proteasome inhibitors in oncology and autoimmune diseases," Current Opinion in Drug Discovery and Development, vol.11, no.5, pp. 616-625, 2008.
138. B. S. Moore, A. S. Eustaquio, and R. P. McGlinchey, "Advances in and applications of proteasome inhibitors," Current Opinion in Chemical Biology, vol.12, no.4, pp. 434-440, 2008.
139. J. Brun, "Proteasome inhibition as a novel therapy in treating rheumatoid arthritis," Medical Hypotheses,vol.71,no.1,pp. 65-72, 2008.
140. U. G. Bhat, M. Halasi, and A. L. Gartel, "FoxM1 is a general target for proteasome inhibitors," PLoS ONE, vol.4, no.8, article e6593, 2009.
141. C. Berges, H. Haberstock, D. Fuchs, et al., "Proteasome inhibition activates the mitochondrial pathway of apoptosis inhumanCD4+Tcells,"Journal of Cellular Biochemistry, vol.108, no.4, pp. 935-946, 2009.
142. J. W. van der Heijden, R. Oerlemans, W. F. Lems, R. J. Scheper, B. A. C. Dijkmans, and G. Jansen, "The proteasome inhibitor bortezomib inhibits the release of NF-κB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients," Clinical and Experimental Rheumatology, vol.27, no.1, pp. 92-98, 2009.
143. J. A. Roman-Blas and S. A. Jimenez, "Targeting NF-kappa;B: a promising molecular therapy in inflammatory arthritis," International Reviews of Immunology, vol.27, no.5, pp. 351-374, 2008.
144. L. Rifas and M. N. Weitzmann, "A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner," Arthritis and Rheumatism, vol.60, no.11, pp. 3324-3335, 2009.
145. H. B. Kwak, M. S. Lee, H. S. Kim, et al., "Proteasome inhibitors induce osteoclast survival by activating the Akt pathway," Biochemical and Biophysical Research Communications, vol.377, no.1, pp. 1-6, 2008.